Literature DB >> 28188176

Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2.

Sadam Yaseen1,2,3, Gregory Demopulos2, Thomas Dudler2, Munehisa Yabuki2, Christi L Wood2, W Jason Cummings2, Larry W Tjoelker2, Teizo Fujita4, Steven Sacks5, Peter Garred6, Peter Andrew1, Robert B Sim1, Peter J Lachmann7, Russell Wallis1, Nicholas Lynch1, Wilhelm J Schwaeble8.   

Abstract

All 3 activation pathways of complement-the classic pathway (CP), the alternative pathway, and the lectin pathway (LP)- converge into a common central event: the cleavage and activation of the abundant third complement component, C3, via formation of C3-activating enzymes (C3 convertases). The fourth complement component, C4, and the second component, C2, are indispensable constituents of the C3 convertase complex, C4bC2a, which is formed by both the CP and the LP. Whereas in the absence of C4, CP can no longer activate C3, LP retains a residual but physiologically critical capacity to convert native C3 into its activation fragments, C3a and C3b. This residual C4 and/or C2 bypass route is dependent on LP-specific mannan-binding lectin-associated serine protease-2. By using various serum sources with defined complement deficiencies, we demonstrate that, under physiologic conditions LP-specific C4 and/or C2 bypass activation of C3 is mediated by direct cleavage of native C3 by mannan-binding lectin-associated serine protease-2 bound to LP-activation complexes captured on ligand-coated surfaces.-Yaseen, S., Demopulos, G., Dudler, T., Yabuki, M., Wood, C. L., Cummings, W. J., Tjoelker, L. W., Fujita, T., Sacks, S., Garred, P., Andrew, P., Sim, R. B., Lachmann, P. J., Wallis, R., Lynch, N., Schwaeble, W. J. Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2. © FASEB.

Entities:  

Keywords:  activation bypass; innate immunity; opsonization; post-ischemic inflammation

Mesh:

Substances:

Year:  2017        PMID: 28188176     DOI: 10.1096/fj.201601306R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  18 in total

1.  The Benefits of Complement Measurements for the Clinical Practice.

Authors:  Anne Grunenwald; Lubka T Roumenina
Journal:  Methods Mol Biol       Date:  2021

2.  The Pneumococcal Surface Proteins PspA and PspC Sequester Host C4-Binding Protein To Inactivate Complement C4b on the Bacterial Surface.

Authors:  Kashif S Haleem; Youssif M Ali; Hasan Yesilkaya; Thomas Kohler; Sven Hammerschmidt; Peter W Andrew; Wilhelm J Schwaeble; Nicholas J Lynch
Journal:  Infect Immun       Date:  2018-12-19       Impact factor: 3.441

Review 3.  Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage.

Authors:  Rossana Franzin; Alessandra Stasi; Marco Fiorentino; Giovanni Stallone; Vincenzo Cantaluppi; Loreto Gesualdo; Giuseppe Castellano
Journal:  Front Immunol       Date:  2020-05-07       Impact factor: 7.561

Review 4.  Collectin-11 (CL-11) Is a Major Sentinel at Epithelial Surfaces and Key Pattern Recognition Molecule in Complement-Mediated Ischaemic Injury.

Authors:  Christopher L Nauser; Mark C Howard; Giorgia Fanelli; Conrad A Farrar; Steven Sacks
Journal:  Front Immunol       Date:  2018-09-06       Impact factor: 7.561

Review 5.  Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.

Authors:  József Dobó; Andrea Kocsis; Péter Gál
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

Review 6.  The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.

Authors:  Dana V Rizk; Nicolas Maillard; Bruce A Julian; Barbora Knoppova; Todd J Green; Jan Novak; Robert J Wyatt
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

7.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

8.  Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins.

Authors:  Youssif M Ali; Matteo Ferrari; Nicholas J Lynch; Sadam Yaseen; Thomas Dudler; Sasha Gragerov; Gregory Demopulos; Jonathan L Heeney; Wilhelm J Schwaeble
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

9.  Human stem cell-derived retinal epithelial cells activate complement via collectin 11 in response to stress.

Authors:  Giorgia Fanelli; Anai Gonzalez-Cordero; Peter J Gardner; Qi Peng; Milan Fernando; Magdalena Kloc; Conrad A Farrar; Arifa Naeem; Peter Garred; Robin R Ali; Steven H Sacks
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

Review 10.  Complement in the Initiation and Evolution of Rheumatoid Arthritis.

Authors:  V Michael Holers; Nirmal K Banda
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.